27 research outputs found
A Complex Case of Pulmonary Silico-Tuberculosis and Review of Literature
Silicosis caused by the inhalation/deposition of free silica particles is characterized by pulmonary inflammation/fibrosis. Among the clinical disorders associated with silicosis, tuberculosis is by far the most prominent. A 66-year-old male non-smoker, originally from North Africa, reported a dry cough and significant weight loss. He was a foundry worker. He had a medical history of bladder carcinoma associated with schistosomiasis. Computed tomography (CT) and positron emission tomography (PET)/CT showed bilateral multiple hypermetabolic lung nodules, some with cavitation. The patient underwent surgical resection of the largest nodule, which was highly suspicious of lung metastasis. The histological examination revealed multiple nodular formations. Several lesions showed the characteristic features of silicotic nodules. There were also adjacent well-formed granulomas, some with central caseous necrosis. A real-time polymerase chain reaction, performed for the identification and quantification of the DNA of the Mycobacterium tuberculosis complex, was positive. Pulmonary silico-tuberculosis is often encountered in patients with a history of silica exposure in tuberculosis-endemic areas. This case serves as a reminder to never underestimate patient occupational exposure and geographic origin. A careful histological diagnosis and molecular investigation are mandatory when approaching difficult cases, especially patients with a prior cancer history and clinical/radiological features suggestive of tumour recurrence/metastasis
A PC-Based Instrument for Automatic Monitoring and Control of a CPVT Power Plant
A PC-based instrument has been developed for the monitoring and control of a concentrated photovoltaic and thermal (CPVT) power plant. The instrument allows acquiring both electrical and thermal quantities. Moreover it implements the solar tracking algorithm used to optimize the power production
Competing risks and prognostic stages of cirrhosis: A 25-year inception cohort study of 494 patients
Background Morphological, haemodynamic and clinical stages of cirrhosis have been proposed, although no definite staging system is yet accepted for clinical practice. Aim To investigate whether clinical complications of cirrhosis may define different prognostic disease stages. Methods Analysis of the database from a prospective inception cohort of 494 patients. Decompensation was defined by ascites, bleeding, jaundice or encephalopathy. Explored potential prognostic stages: 1, compensated cirrhosis without oesophago-gastric varices; 2, compensated cirrhosis with varices; 3, bleeding without other complications; 4, first nonbleeding decompensation; 5, any second decompensating event. Patient flow across stages was assessed by a competing risks analysis. Results Major patient characteristics were: 199 females, 295 males, 404 HCV+, 377 compensated, 117 decompensated cirrhosis. The mean follow-up was 145 ± 109 months without dropouts. Major events: 380 deaths, 326 oesophago-gastric varices, 283 ascites, 158 bleeding, 146 encephalopathy, 113 jaundice, 126 hepatocellular carcinoma and 19 liver transplantation. Patients entering each prognostic stage along the disease course were: 202, stage 1; 216, stage 2; 75 stage 3; 206 stage 4; 213 stage 5. Five-year transition rate towards a different stage, for stages 1-4 was 34.5%, 42%, 65% and 78%, respectively (P < 0.0001); 5-year mortality for stages 1-5 was 1.5%, 10%, 20%, 30% and 88% respectively (P < 0.0001). An exploratory analysis showed that this patient stratification may configure a prognostic system independent of the Child-Pugh score, Model for End Stage Liver Disease and comorbidity. Conclusion The development of oesophago-gastric varices and decompensating events in cirrhosis identify five prognostic stages with significantly increasing mortality risks
α1-Antitrypsin Polymerizes in Alveolar Macrophages of Smokers With and Without α1-Antitrypsin Deficiency
BACKGROUND: The deficiency of α1-antitrypsin (AAT) is secondary to misfolding and polymerization of the abnormal Z-AAT in liver cells and is associated with lung emphysema. Alveolar macrophages (AM) produce AAT, however it is not known if Z-AAT can polymerize in AM, further decreasing lung AAT and promoting lung inflammation. AIMS: To investigate if AAT polymerizes in human AM and to study the possible relation between polymerization and degree of lung inflammation. METHODS: Immunohistochemical analysis with 2C1 monoclonal antibody specific for polymerized AAT was performed in sections of: 9 lungs from individuals with AAT deficiency (AATD) and severe COPD, 35 smokers with normal AAT levels of which 24 with severe COPD and 11 without COPD, and 13 non-smokers. AM positive for AAT polymers were counted and expressed as percentage of total AM in lung. RESULTS: AAT polymerization was detected in [27(4-67)%] of AM from individuals with AATD but also in AM from smokers with normal AAT with [24(0-70)%] and without [24(0-60)%] COPD, but not in AM from non-smokers [0(0-1.5)%] (p<0.0001). The percentage of AM with polymerized AAT correlated with pack-years smoked (r=0.53,p=0.0001), FEV1/FVC (r=-0.41,p=0.005), Small Airways Disease (r=0.44,p=0.004), number of CD8+T-cells and neutrophils in alveolar walls (r=0.51,p=0.002; r=0.31,p=0.05 respectively). CONCLUSIONS: Polymerization of AAT in alveolar macrophages occurs in lungs of individuals with AATD but also in smokers with normal AAT levels with or without COPD. Our findings highlight the similarities in the pathophysiology of COPD in individuals with and without AATD, adding a potentially important step to the mechanism of COPD
Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts
Assessing covariate imbalance in meta-analysis studies
The main goal of meta-analysis is to combine data across studies or data sets to obtain summary estimates. In
this paper, the novelty is to propose a statistical tool to assess a possible covariate imbalance in baseline variables
to investigate similarity of trials. We conducted the detection of the covariate imbalance, first, through some
graphical comparison of the empirical cumulative distribution functions or ECDFs, which are built by putting
together arms or trials according to some risk factor, and second, through some non-parametric tests such as the
Kolmogorov–Smirnov and the Anderson–Darling tests. To overcome the huge presence of ties, we conducted the
statistical tests on perturbed versions of the original data sets. The applications concern two real meta-analyses
of RCTs: the first one, on interferon-alpha treatment of chronic hepatitis C, with 107 studies involved, and the
second one, on cholesterol-lowering treatment with statins, with 14 studies involved.
The applications allow for analysis of both when risk factors reflecting demographic or clinical differences
in experimental and control arms are balanced or not and when there are structural differences between the
levels of some study variables, in order to proceed eventually with the pooling of the studies. We developed our
suggestion, which is a quantitative way to assess combinability in meta-analysis, only with respect to RCTs, but
it could be applied to a minor extent to non-RCTs. Copyright © 2011 John Wiley & Sons, Ltd
Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn's disease.
1. Aliment Pharmacol Ther. 2008 Jun;27(12):1210-23. Epub 2008 Mar 14.
Meta-analysis: remission and response from control arms of randomized trials of
biological therapies for active luminal Crohn's disease.
Tinè F, Rossi F, Sferrazza A, Orlando A, Mocciaro F, Scimeca D, Olivo M, Cottone
M.
Divisione di Gastroenterologia, Azienda Ospedaliera V. Cervello, Palermo, Italy.
[email protected]
BACKGROUND: Remission and response are the main outcomes to evaluate the efficacy
of new treatments for Crohn's disease (CD).
AIM: To explain variation of remission and response rates in active luminal CD.
METHODS: We studied control patients from trials of biological therapies through
articles retrieved by MEDLINE search (from 1997 to 2007) and by bibliography
review. Thousand nine hundred and thirteen control patients from 28 trials were
identified; data were extracted by three independent observers and pooled by
DerSimonian and Laird random effect model; factors influencing remission and
clinical response were explored by metaregression for aggregated data.
RESULTS: The pooled control rates of remission and response were 17% and 33%,
respectively, both with significant heterogeneity among studies (P < 0.0001). At
metaregression, the time of primary outcome evaluation was associated with
remission, whereas the trial's criteria for defining response and publication
year were predictors of response. CDAI score, CRP levels or other clinical
variables related with disease activity or concomitant medications were not
significant factors.
CONCLUSIONS: Populations used as 'add-on' treatment comparator in trials of
biological therapies for active luminal CD are poorly characterized and outcomes
are heterogeneous. Planning of future trials will require better description of
patients and concomitant therapies, blinding of outcome assessors and homogeneous
criteria of outcome definition
An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C
Purpose: Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months. We aimed to assess safety and predictors of discontinuation or dose modification of these drugs.
Methods: Observational study of 312 patients with predominantly genotype 1 chronic hepatitis C treated openly along 5 years in a clinical practice setting.
Results: Eighty-four percent of patients experienced at least one adverse event (853 events in total, 3.3 per patient on average). Incidence rate was higher during the first 90 days and decreased thereafter (<5%). Discontinuation rates at 30 and 90 days and at end of treatment were 2, 4 and 8%, respectively. Seventy percent of discontinuation cases were due to adverse events rather than to laboratory abnormalities. Serious adverse events were rare (<1%). Dose modifications were made in 158 patients (51%) on 237 occasions. After adjusting for covariates, older age was a predictor of early discontinuation, whereas HCV genotypes 1–4 and daily ribavirin dose of 1000 mg or more were predictors of dose modification.
Conclusions: The majority of real-world patients with chronic hepatitis C tolerate acceptably dual therapy and very few discontinue it. Subjective decisions on dose reduction of either compound appears to have a major impact on adherence of patients. There is a need to better define, collect and analyse clinical features which may predict adverse events and safety-related decisions during therapy of chronic hepatitis C
Reconstruction of Holocene environmental changes in two archaeological sites of Calabria (Southern Italy) using an integrated pedological and anthracological approach.
This paper focuses on the reconstruction of Holocene climatic and environmentalchanges in twoarchaeologicalsites of southwestern and north-central Calabria (southernItaly). It is based on a comparison of geoarchaeological, pedological and pedoanthracological data from soil profiles in the coastal hilly and inland mountainous surroundings of Palmi and Cecita Lake, respectively